Measuring Cell Line Development Quality Within Days of Single-Cell Cloning, Not Months Later
For nearly a decade, the Beacon platform has advanced from integrated single-cell cloning to earlier productivity, product-quality, and stability measurements, with AI-assisted clone evaluation pointing toward the next step. Bringing richer evidence forward helps teams focus resources on the candidates most likely to succeed. The post Measuring Cell Line Development Quality Within Days of…
Monoclonal antibody (mAb) dominance in cell line development (CLD) campaigns has shifted, with bispecific antibodies, ADCs, and other complex formats now making up a larger share of the pipeline. Traditional clone selection methods often relied on titer measurements, but these do not fully capture whether a clone consistently produces the intended molecule.
Early assessment of product quality during single-cell cloning is crucial to avoid advancing weak candidates. The Beacon ® optofluidics platform, utilized by 38% of surveyed teams, offers a solution by providing growth, productivity, and product-quality data within days of single-cell cloning. Studies have shown that using this platform can reduce CLD timelines by up to eight weeks and improve clone productivity.
Early detection of aggregation and incorrect chain pairing through on-chip assays, such as those from GSK, enables better candidate prioritization before costly fed-batch testing. The Beacon platform has evolved to include AI-assisted clone evaluation, helping teams focus resources on promising candidates and reducing the number of weak clones progressing to later stages.
This shift from relying solely on titer measurements to incorporating product-quality assessments during early stages represents a significant advancement in CLD.
Written by urgent.news from GEN Biotechnology's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
